Collaborative and Other Relationships (Tables)

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:




After LUNSUMIO Approval until the First Threshold Date	37.5	%
After First Threshold Date until the Second Threshold Date	35.0	%
After Second Threshold Date	30.0	%

Pretax profit sharing formula

Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:



Until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Summary of activity related to Aducanumab collaboration

A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:


	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
(In millions)		2022			2022
Total ADUHELM Collaboration development expense		$	34.6		$	116.0
Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income		19.0			63.8
Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement		(8.0)			127.8
Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income		(3.9)			68.1

Summary of activity related to the UCB collaboration

A summary of development expense related to the UCB collaboration agreement is as follows:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2023		2022		2023		2022
Total UCB collaboration development expense	$	13.6	$	18.3	$	46.2	$	51.5
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	6.8		9.1		23.1		25.7

Summary of Activity Related to Denali Therapeutics Collaboration

A summary of development expense related to the Denali collaboration is as follows:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2023		2022		2023		2022
Total Denali collaboration development expense	$	12.6	$	19.9	$	51.3	$	58.0
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	7.6		11.4		30.8		33.5

Summary of Activity Related to BAN2401 and Elenbecestat Collaboration


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2023		2022		2023		2022
Total development expense incurred by the collaboration related to the advancement of LEQEMBI	$	88.5	$	109.3	$	282.6	$	264.9
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	44.3		54.7		141.3		132.5
Total sales and marketing expense incurred by the LEQEMBI Collaboration	163.4		29.0		191.0		68.3
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income	81.7		14.5		95.5		34.2

Summary of Activity Related to Sage Therapeutics

A summary of development and sales and marketing expense related to the Sage collaboration is as follows:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
(In millions)	2023		2022		2023		2022
Total Sage collaboration development expense	$	72.0	$	40.9	$	158.9	$	130.4
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income	36.0		20.5		79.5		65.2
Total sales and marketing expense incurred by the Sage collaboration	54.0		28.5		152.3		69.9
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income	27.0		14.2		76.1		34.9